<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01141</drugbank-id>
  <drugbank-id>APRD01114</drugbank-id>
  <name>Micafungin</name>
  <description>Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.</description>
  <cas-number>235114-32-6</cas-number>
  <unii>R10H71BSWG</unii>
  <average-mass>1270.274</average-mass>
  <monoisotopic-mass>1269.438350313</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A541</ref-id>
        <pubmed-id>20606829</pubmed-id>
        <citation>Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.</citation>
      </article>
      <article>
        <ref-id>A1931</ref-id>
        <pubmed-id>20054447</pubmed-id>
        <citation>Bormann AM, Morrison VA: Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther. 2009 Dec 29;3:295-302.</citation>
      </article>
      <article>
        <ref-id>A1933</ref-id>
        <pubmed-id>17661660</pubmed-id>
        <citation>Vehreschild JJ, Cornely OA: Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol. 2006 Aug;1(2):161-70.</citation>
      </article>
      <article>
        <ref-id>A1936</ref-id>
        <pubmed-id>15882123</pubmed-id>
        <citation>Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509.</citation>
      </article>
      <article>
        <ref-id>A1938</ref-id>
        <pubmed-id>16575738</pubmed-id>
        <citation>Chandrasekar PH, Sobel JD: Micafungin: a new echinocandin. Clin Infect Dis. 2006 Apr 15;42(8):1171-8. Epub 2006 Mar 14.</citation>
      </article>
      <article>
        <ref-id>A1939</ref-id>
        <pubmed-id>17516879</pubmed-id>
        <citation>Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.</citation>
      </article>
      <article>
        <ref-id>A1941</ref-id>
        <pubmed-id>17504145</pubmed-id>
        <citation>Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, Barrett D, Aoki Y: Role of micafungin in the antifungal armamentarium. Curr Med Chem. 2007;14(11):1263-75.</citation>
      </article>
      <article>
        <ref-id>A784</ref-id>
        <pubmed-id>19724014</pubmed-id>
        <citation>Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep  1.</citation>
      </article>
      <article>
        <ref-id>A787</ref-id>
        <pubmed-id>16960253</pubmed-id>
        <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703.</citation>
      </article>
      <article>
        <ref-id>A788</ref-id>
        <pubmed-id>16990627</pubmed-id>
        <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive &lt;i&gt;Candida&lt;/i&gt; infections, as well as esophageal candidiasis, and prophylaxis of &lt;i&gt;Candida&lt;/i&gt; infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.&#13;
&#13;
Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.</indication>
  <pharmacodynamics>Formerly known as FK463, micafungin is a semisynthetic lipopeptide synthesized from a fermentation product of &lt;i&gt;Coleophoma empetri&lt;/i&gt; that works as an antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis. Depending on its concentration, micafungin may be fungicidal against some &lt;i&gt;Candida&lt;/i&gt;, but is usually fungistatic against &lt;i&gt;Apergillus&lt;/i&gt;. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.</pharmacodynamics>
  <mechanism-of-action>Micafungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls which is not present in mammalian cells. It does this by inhibiting beta-1,3-D-glucan synthase.</mechanism-of-action>
  <toxicity>Intravenous LD&lt;sub&gt;50&lt;/sub&gt; in rats is 125mg/kg. In dogs it is &gt;200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.</toxicity>
  <metabolism>Micafungin is metabolized to M-1 (catechol form) by arylsulfatase, with further metabolism to M-2 (methoxy form) by catechol-O-methyltransferase. M-5 is formed by hydroxylation at the side chain (w-1 position) of micafungin catalyzed by cytochrome P450 (CYP) isozymes. Even though micafungin is a substrate for and a weak inhibitor of CYP3A in vitro, hydroxylation by CYP3A is not a major pathway for micafungin metabolism in vivo.</metabolism>
  <absorption>Not absorbed orally</absorption>
  <half-life>14-17 hours</half-life>
  <protein-binding>Highly (&gt;99%) protein bound in vitro, independent of plasma concentrations over the range of 10 to 100 &amp;micro;g/mL. The primary binding protein is albumin; however, micafungin, at therapeutically relevant concentrations, does not competitively displace bilirubin binding to albumin. Micafungin also binds to a lesser extent to a&lt;sub&gt;1&lt;/sub&gt;-acid-glycoprotein.</protein-binding>
  <route-of-elimination>Fecal excretion is the major route of elimination (total radioactivity at 28 days was 71% of the administered dose).</route-of-elimination>
  <volume-of-distribution>* 0.39 ± 0.11 L/kg [adult patients with esophageal candidiasis]</volume-of-distribution>
  <clearance>* 0.359 +/- 0.179 mL/min/kg [Adult Patients with IC with 100 mg]&#13;
* 0.321 +/- 0.098 mL/min/kg [HIV- Positive Patients with EC with 50 mg]&#13;
* 0.327 +/- 0.093 mL/min/kg [HIV- Positive Patients with EC with 100 mg]&#13;
* 0.340 +/- 0.092 mL/min/kg [HIV- Positive Patients with EC with 150 mg]&#13;
* 0.214 +/- 0.031 mL/min/kg [hematopoietic stem cell transplant recipients 3 mg/kg]&#13;
* 0.204 +/- 0.036 mL/min/kg [hematopoietic stem cell transplant recipients 4 mg/kg]&#13;
* 0.224 +/- 0.064 mL/min/kg [hematopoietic stem cell transplant recipients 6 mg/kg]&#13;
* 0.223 +/- 0.081 mL/min/kg [hematopoietic stem cell transplant recipients 8 mg/kg]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.</description>
    <direct-parent>Oligopeptides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Alkanolamines</alternative-parent>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzamides</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Cyclic peptides</alternative-parent>
    <alternative-parent>Fatty amides</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Isoxazoles</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Macrolactams</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Phenol ethers</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Phenylsulfates</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Pyrrolidines</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Sulfuric acid monoesters</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alkanolamine</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Alpha-oligopeptide</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Arylsulfate</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Cyclic alpha peptide</substituent>
    <substituent>Ether</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Isoxazole</substituent>
    <substituent>Lactam</substituent>
    <substituent>Macrolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic sulfuric acid or derivatives</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Phenylsulfate</substituent>
    <substituent>Polyol</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Sulfate-ester</substituent>
    <substituent>Sulfuric acid ester</substituent>
    <substituent>Sulfuric acid monoester</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001165</drugbank-id>
      <name>Micafungin sodium</name>
      <unii>IS1UP79R56</unii>
      <cas-number>208538-73-2</cas-number>
      <inchikey>KOOAFHGJVIVFMZ-WZPXRXMFSA-M</inchikey>
      <average-mass>1292.27</average-mass>
      <monoisotopic-mass>1291.420295</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Micafungin</synonym>
    <synonym language="spanish" coder="">Micafungina</synonym>
  </synonyms>
  <products>
    <product>
      <name>Mycamine</name>
      <labeller>Astellas Pharma US, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0469-3250</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-03-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021506</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mycamine</name>
      <labeller>Astellas Pharma US, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0469-3211</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021506</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mycamine</name>
      <labeller>Astellas Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02294222</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mycamine</name>
      <labeller>Astellas Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311054</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Mycamine</name>
      <ingredients>Micafungin</ingredients>
    </mixture>
    <mixture>
      <name>Mycamine</name>
      <ingredients>Micafungin</ingredients>
    </mixture>
    <mixture>
      <name>Mycamine</name>
      <ingredients>Micafungin</ingredients>
    </mixture>
    <mixture>
      <name>Mycamine</name>
      <ingredients>Micafungin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Astellas Pharma Inc.</name>
      <url>http://www.astellas.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Mycamine 50 mg vial</description>
      <cost currency="USD">112.2</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Mycamine 100 mg vial</description>
      <cost currency="USD">224.4</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antifungal Agents</category>
      <mesh-id>D000935</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antimycotics for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>COMT Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Echinocandin Antifungal</category>
      <mesh-id/>
    </category>
    <category>
      <category>Echinocandins</category>
      <mesh-id>D054714</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Lipopeptides</category>
      <mesh-id>D055666</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Peptides, Cyclic</category>
      <mesh-id>D010456</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Aspergillis, Candida and other fungi</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>10 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J02AX05">
      <level code="J02AX">Other antimycotics for systemic use</level>
      <level code="J02A">ANTIMYCOTICS FOR SYSTEMIC USE</level>
      <level code="J02">ANTIMYCOTICS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:14.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01141.pdf?1265922795</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01141.pdf?1265922736</msds>
  <patents>
    <patent>
      <number>5376634</number>
      <country>United States</country>
      <approved>1994-12-27</approved>
      <expires>2011-12-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2202058</number>
      <country>Canada</country>
      <approved>2007-11-06</approved>
      <expires>2015-09-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2044746</number>
      <country>Canada</country>
      <approved>2001-08-07</approved>
      <expires>2011-06-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6107458</number>
      <country>United States</country>
      <approved>2000-08-22</approved>
      <expires>2019-03-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6265536</number>
      <country>United States</country>
      <approved>2001-07-24</approved>
      <expires>2015-09-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6774104</number>
      <country>United States</country>
      <approved>2004-08-10</approved>
      <expires>2021-01-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The metabolism of Sirolimus can be decreased when combined with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The metabolism of Temsirolimus can be decreased when combined with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Dicoumarol can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The therapeutic efficacy of Phenindione can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The therapeutic efficacy of Warfarin can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The therapeutic efficacy of Coumarin can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Fluindione can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Clorindione can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Diphenadione can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The therapeutic efficacy of Tioclomarol can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Micafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The metabolism of Micafungin can be decreased when combined with Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The metabolism of Micafungin can be decreased when combined with Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The metabolism of Micafungin can be decreased when combined with Testosterone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02105</drugbank-id>
      <name>3,5-Dinitrocatechol</name>
      <description>The metabolism of Micafungin can be decreased when combined with 3,5-Dinitrocatechol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The metabolism of Micafungin can be decreased when combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11632</drugbank-id>
      <name>Opicapone</name>
      <description>The metabolism of Micafungin can be decreased when combined with Opicapone.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.67</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.18e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-6.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>{5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzamido)-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>micafungin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1270.274</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1269.438350313</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C56H71N9O23S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>PIEUQSKUWLMALL-YABMTYFHSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>510.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>303.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>128.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>-2.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Freely soluble as sodium salt (&gt; 200mg/mL)</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20128</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>600520</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>477468</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508208</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C15819</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02465</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>419105</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164781026</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000548</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Micafungin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL457547</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic4/mycamine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/micafungin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004669</id>
      <name>1,3-beta-glucan synthase component FKS1</name>
      <organism>Aspergillus niger (strain CBS 513.88 / FGSC A1513)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A784</ref-id>
            <pubmed-id>19724014</pubmed-id>
            <citation>Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep  1.</citation>
          </article>
          <article>
            <ref-id>A16925</ref-id>
            <pubmed-id>19463275</pubmed-id>
            <citation>Quindos G, Eraso E, Javier Carrillo-Munoz A, Canton E, Peman J: [In vitro antifungal activity of micafungin]. Rev Iberoam Micol. 2009 Mar 31;26(1):35-41. doi: 10.1016/S1130-1406(09)70006-3. Epub 2009 May 7.</citation>
          </article>
          <article>
            <ref-id>A787</ref-id>
            <pubmed-id>16960253</pubmed-id>
            <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703.</citation>
          </article>
          <article>
            <ref-id>A788</ref-id>
            <pubmed-id>16990627</pubmed-id>
            <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20.</citation>
          </article>
          <article>
            <ref-id>A16926</ref-id>
            <pubmed-id>15101786</pubmed-id>
            <citation>Jarvis B, Figgitt DP, Scott LJ: Micafungin. Drugs. 2004;64(9):969-82; discussion 983-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="A2QLK4" source="Swiss-Prot">
        <name>1,3-beta-glucan synthase component FKS1</name>
        <general-function>1,3-beta-d-glucan synthase activity</general-function>
        <specific-function>Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).</specific-function>
        <gene-name>fksA</gene-name>
        <locus/>
        <cellular-location>Mitochondrion</cellular-location>
        <transmembrane-regions>487-507
525-545
564-584
591-611
655-675
707-727
728-748
1329-1349
1386-1406
1473-1493
1497-1517
1588-1608
1630-1650
1666-1686
1701-1721
1766-1786
1826-1846</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>216972.8</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="425011">Aspergillus niger (strain CBS 513.88 / FGSC A1513)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A2QLK4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FKS1_ASPNC</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,3-beta-D-glucan-UDP glucosyltransferase</synonym>
          <synonym>2.4.1.34</synonym>
          <synonym>fks1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013251|1,3-beta-glucan synthase component FKS1
MSGYPAGHYEDGYGHQEHGGDAYYQDEHGQAYYDPNDYGDSYYDRGNYYNAEGGQAYGQE
GGYYDAGHQDDYYGDQYYDQGNGAPRGRRRGDSEEDSETFSDFTMRSETARAADMDYYGR
GDERYNSYADSQYAGRGYNGYRPPSSQVSYGANRSSGASTPVYGMDYGSALPGGPRSREP
YPAWASDGQVPVSKEEIEDIFIDLVNKFGFQRDSMRNMYDHLMTQLDSRASRMTPNQALL
SLHADYIGGDNANYRRWYFAAHLDLDDAVGFANMKLGKADRKTRKARKAAKAAAQQNPEN
VEENLEAMEGDNSLEAAVYRWKSRMNRMSPHDRVRQLALYMLCWGEANQVRYMPECICFI
FKCADDYYSSPECQSRVEPVEEFTYLNEIITPLYQFCRDQGYEILDGKYVRRERDHEKII
GYDDMNQLFWYPEGIERISFEDKTRLVDVPPAERWTKLKDVDWKKAFFKTYRETRSWFHM
ITNFNRIWVIHLGAFWFFTAYNAPTLYTKNYQQQLDNKPAGSKYWSAVGFGGALVGLIQI
LATLCEWMYVPRRWAGAQHLSKRLMFLIAVFIVNLAPGVVVFGFNNVLSETICLIIGIVH
FFIALATFFFFSVMPLGGLFGSYLKKHGRQYVASQTFTASYPRLNGNDMWMSYGLWICVF
GAKLVESYFFLTLSLKDPMRILSPMRIHQCAGVTYIPNSLCHAQPQILLGLMMFMDLTLF
FLDSYLWYVICNTIFSVARSFYLGVSIWSPWRNIFSRLPKRIYSKVLATTDMEIKYKPKV
LISQVWNAIIISMYREHLLAIDHVQKLLYHQVPSEQEGKRTLRAPTFFVSQEDQSFKTEF
FPAGSEAERRISFFAQSVATPMPEPLPVDNMPTFTVLIPHYGEKILLSLREIIREDEPYS
RVTLLEYLKQLHPHEWDCFVKDTKILADETSQLNGEPEKNEKDAQKSKIDDLPFYCIGFK
SAAPEYTLRTRIWSSLRSQTLYRTISGFMNYSRAIKLLYRVENPEVVQMFGGNSEKLERE
LERMARRKFKICVSMQRYAKFNKEERENTEFLLRAYPDLQIAYLDEEPPANEGEEPRLYS
ALIDGHCELLDNGMRKPKFRIQLSGNPILGDGKSDNQNHSIIFYRGEYIQVIDANQDNYL
EECLKIRSVLAEFEELTTDNVSPYTPGIATEAETPVAILGAREYIFSENVGVLGDVAASK
EQTFGTLFARTLAQIGGKLHYGHPDFLNGIFMTTRGGISKAQKGLHLNEDIYAGMTALCR
GGRIKHCEYFQCGKGRDLGFGSILNFTTKIGTGMGEQMLSREYYYLGTQLPLDRFLSFYY
AHPGFHLNNMFIMLSVQMFMIVLINLGALKHETITCRYNSNLPITDPLRPTYCADLTPII
AWVNRCVVSIFIVFFISFVPLAVQELTERGLWRMATRLAKHFGSFSFMFEVFVCQIYANA
VHQNLSFGGARYIGTGRGFATARIPFGVLYSRFAGPSIYAGSRLLLMLLFATSTVWTPAL
IWFWVSLLALCISPFLFNPHQFAWHDFFIDYRDYIRWLSRGNSRSHASSWIAFCRLSRTR
LTGYKRKLLGVPSEKGSGDVPRAKFTNIFFSEIIAPLVQVAVTLVPYLYINSRTGISNDN
ERASNAVVRIAIVAFGPIGVNAGVSGMFFGMACCMGPIFGMCCKKFGAVLAAIAHAIAVI
ILLVIFEVMFFLESWSWPRMVLGMISAAAIQRFIYKLIISLALTREFKHDQSNIAWWTGK
WYNMGWHSLSQPGREFLCKITELGYFSADFVLGHILLFVMLPALCIPYVDKFHSVILFWL
RPSRQIRPPIYSLKQSKLRKRRVVRFAILYFTMLVLFLILLIAPLVARDEGISVNLNIMS
LMQPLDTDNNDTISSYTGNGLPVGYSAWTPSAASASA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013252|1,3-beta-glucan synthase component FKS1 (fksA)
ATGTCAGGCTATCCAGCAGGGCATTACGAGGATGGCTACGGCCACCAGGAGCATGGGGGC
GATGCGTACTACCAGGACGAACATGGCCAGGCTTATTACGATCCTAACGATTACGGTGAC
AGCTATTATGATAGAGGCAATTATTACAACGCAGAAGGAGGTCAGGCATATGGCCAAGAA
GGTGGTTACTACGATGCTGGTCACCAGGATGACTACTACGGTGACCAGTACTATGACCAA
GGAAATGGTGCCCCCCGCGGAAGACGCCGTGGAGATTCTGAGGAGGATTCGGAGACCTTT
AGCGATTTCACCATGAGGTCAGAGACTGCTCGAGCTGCGGATATGGATTACTATGGCCGT
GGAGACGAACGTTACAACAGTTATGCCGACAGCCAGTATGCTGGTCGTGGATACAACGGA
TACCGGCCGCCATCTTCGCAGGTCTCGTATGGCGCCAACCGATCATCTGGCGCTTCGACA
CCCGTATACGGCATGGACTACGGAAGCGCCCTTCCTGGTGGACCGCGTTCTCGGGAGCCG
TACCCAGCCTGGGCATCGGATGGTCAGGTCCCTGTCTCCAAGGAGGAAATCGAAGATATC
TTCATTGACTTGGTCAACAAATTCGGTTTCCAGAGGGACAGCATGCGCAACATGTATGAC
CACCTGATGACACAGTTGGACTCCCGGGCCTCCAGAATGACGCCCAACCAAGCCCTTCTG
TCTCTGCACGCAGACTACATTGGTGGTGACAATGCCAACTACCGCCGTTGGTATTTTGCT
GCCCATCTGGATTTGGACGATGCCGTGGGATTCGCCAACATGAAGCTGGGCAAAGCAGAC
CGGAAGACCAGGAAAGCTCGCAAAGCGGCCAAGGCGGCAGCACAGCAGAACCCTGAAAAC
GTCGAGGAGAACCTGGAGGCCATGGAAGGCGACAACAGCCTGGAAGCCGCTGTTTACAGG
TGGAAGAGCCGCATGAACCGCATGTCCCCGCATGATCGTGTGCGCCAATTGGCTCTGTAC
ATGCTGTGCTGGGGTGAAGCTAACCAGGTCCGGTACATGCCTGAGTGCATTTGCTTCATC
TTCAAGTGTGCGGATGATTACTACAGCTCCCCTGAATGCCAGAGCCGGGTTGAGCCGGTG
GAGGAATTCACTTACCTGAATGAGATCATTACCCCCCTCTATCAGTTCTGCCGTGACCAG
GGTTACGAAATCTTGGATGGCAAGTATGTTCGCCGCGAGCGTGATCACGAGAAGATCATC
GGATACGATGATATGAACCAGCTTTTCTGGTACCCCGAGGGTATCGAACGCATCTCATTC
GAGGATAAGACTCGTCTTGTCGATGTCCCCCCAGCTGAAAGATGGACCAAGTTGAAGGAC
GTCGACTGGAAGAAAGCATTCTTCAAGACGTACAGAGAGACTCGGTCCTGGTTCCACATG
ATCACCAACTTCAACCGTATCTGGGTTATTCACCTGGGTGCTTTCTGGTTCTTCACTGCT
TATAACGCCCCCACCTTGTATACCAAGAACTACCAGCAGCAGCTGGACAATAAGCCCGCT
GGTTCAAAGTATTGGTCTGCTGTCGGTTTTGGTGGTGCCCTGGTTGGATTAATTCAGATC
TTGGCAACGCTCTGTGAGTGGATGTACGTGCCTCGCCGGTGGGCAGGTGCTCAGCATCTC
AGCAAGCGTCTTATGTTCCTTATCGCCGTTTTCATTGTCAATCTTGCTCCTGGTGTCGTG
GTCTTCGGTTTCAACAATGTTCTCAGTGAGACAATCTGCCTCATCATTGGTATCGTCCAC
TTCTTCATTGCTCTGGCCACGTTCTTCTTTTTCTCCGTCATGCCTCTTGGAGGTCTGTTC
GGCAGTTACCTGAAGAAGCACGGCCGTCAATATGTGGCCAGTCAGACATTCACGGCGAGC
TACCCTCGCCTGAATGGCAACGACATGTGGATGTCTTATGGTCTGTGGATCTGTGTTTTC
GGTGCGAAGCTGGTCGAGTCTTACTTCTTCCTGACTCTGTCATTGAAGGATCCCATGCGT
ATCTTGTCGCCGATGCGTATCCATCAGTGTGCTGGTGTGACATACATCCCGAACAGCCTT
TGCCACGCCCAGCCTCAGATTCTGCTGGGTCTGATGATGTTCATGGATTTGACTCTTTTC
TTCCTGGATAGTTATCTGTGGTATGTCATTTGTAACACCATCTTCTCGGTGGCTCGGTCC
TTCTACCTGGGTGTCTCCATCTGGTCGCCCTGGAGAAACATCTTCTCTCGCCTACCGAAG
CGTATCTATTCGAAGGTCTTGGCTACGACCGACATGGAGATCAAGTACAAGCCCAAGGTG
CTCATTTCCCAAGTTTGGAACGCCATCATCATCTCCATGTACCGTGAGCATCTGCTGGCG
ATTGATCACGTCCAGAAGTTGCTTTACCACCAGGTTCCCTCCGAACAGGAGGGCAAGCGT
ACCCTGCGGGCTCCTACCTTCTTCGTTTCGCAGGAAGACCAGTCCTTCAAGACTGAGTTC
TTCCCCGCGGGTAGTGAGGCTGAGCGCCGTATCTCCTTCTTTGCCCAGTCGGTCGCTACC
CCCATGCCTGAGCCTCTTCCGGTTGACAACATGCCCACTTTCACTGTCCTTATCCCCCAT
TACGGAGAGAAGATTCTGCTGTCGTTGCGTGAAATCATTCGTGAGGATGAGCCGTACTCT
CGCGTTACTCTCCTGGAATACCTGAAACAGCTCCACCCCCACGAGTGGGACTGCTTCGTC
AAGGACACAAAGATTCTGGCTGATGAGACCTCACAACTCAACGGCGAACCCGAGAAGAAC
GAGAAGGATGCGCAGAAGAGCAAGATCGACGACCTTCCCTTCTATTGCATCGGTTTCAAG
TCTGCCGCTCCCGAATACACGCTCCGTACCCGTATCTGGTCCTCTCTGCGCTCTCAGACC
CTGTACAGAACCATTTCCGGTTTCATGAACTACAGCAGGGCCATCAAGCTCCTTTACCGT
GTCGAAAACCCCGAGGTCGTCCAGATGTTTGGTGGTAACTCCGAGAAGCTCGAACGTGAG
CTTGAAAGGATGGCGCGCCGCAAGTTCAAGATCTGTGTCTCAATGCAACGTTACGCCAAG
TTCAACAAGGAAGAGCGTGAAAACACCGAGTTCCTTCTCCGTGCCTACCCTGATCTCCAA
ATCGCTTACCTTGACGAGGAACCCCCTGCCAATGAGGGTGAGGAGCCCCGCTTGTACTCG
GCTTTGATTGATGGACACTGTGAGCTCCTCGACAACGGAATGCGCAAGCCGAAGTTCAGA
ATTCAGCTCTCCGGAAACCCTATCCTGGGTGACGGCAAGTCCGATAACCAGAACCACTCT
ATCATCTTCTACCGCGGTGAATACATCCAGGTCATTGACGCTAACCAGGATAACTACCTG
GAGGAGTGTCTCAAGATCCGTAGCGTTCTGGCTGAGTTCGAAGAACTTACCACCGACAAT
GTCTCGCCCTACACTCCTGGTATTGCCACCGAAGCTGAGACCCCAGTCGCCATTCTCGGT
GCTCGTGAATACATTTTCTCTGAGAATGTTGGTGTTCTTGGTGACGTTGCTGCCAGTAAG
GAACAGACGTTCGGTACCCTGTTTGCTCGTACCCTTGCGCAGATTGGTGGAAAGCTGCAT
TATGGTCACCCTGATTTCCTAAACGGTATCTTCATGACGACGCGTGGTGGTATCTCCAAG
GCTCAGAAGGGTCTCCACCTGAACGAGGATATTTATGCTGGTATGACTGCTTTGTGCCGT
GGTGGACGCATCAAGCATTGCGAGTACTTCCAGTGTGGTAAGGGTCGTGATTTGGGTTTC
GGCTCCATTCTGAACTTCACAACCAAGATTGGTACTGGTATGGGTGAGCAGATGCTGTCC
AGAGAGTACTACTATCTCGGAACACAGCTGCCCCTCGATCGCTTCCTGTCTTTCTACTAT
GCTCACCCTGGTTTCCATCTTAACAACATGTTCATTATGTTGTCTGTGCAGATGTTCATG
ATCGTTCTGATCAACCTTGGTGCTCTGAAGCATGAGACTATTACATGCCGTTACAACTCG
AACCTGCCCATTACTGACCCTCTGCGTCCCACGTACTGTGCTGATCTTACCCCCATTATC
GCCTGGGTGAACCGTTGCGTCGTTTCCATCTTCATTGTGTTCTTCATCTCCTTCGTTCCC
CTGGCCGTCCAGGAATTGACTGAGAGGGGTCTTTGGCGCATGGCTACTCGTCTGGCCAAG
CACTTTGGTTCCTTCTCCTTCATGTTCGAGGTGTTTGTCTGCCAAATCTACGCCAATGCT
GTTCACCAGAACCTTTCCTTCGGCGGTGCTCGCTACATCGGTACTGGACGTGGTTTCGCT
ACGGCTCGTATCCCATTCGGTGTCTTGTACTCCCGTTTCGCTGGACCATCCATCTATGCC
GGTTCTCGTTTGCTGCTCATGCTTCTGTTTGCGACATCCACTGTCTGGACACCAGCCCTG
ATCTGGTTCTGGGTTTCTCTGCTTGCTCTCTGCATTTCCCCCTTCCTGTTCAACCCCCAC
CAGTTTGCTTGGCACGATTTCTTTATCGACTACCGCGATTACATCAGATGGCTGTCCCGT
GGTAACTCTCGCTCGCACGCTTCGTCCTGGATCGCCTTCTGCCGCCTGTCTCGTACCCGT
CTCACTGGTTACAAGCGCAAGCTTCTTGGTGTTCCTTCGGAGAAGGGATCTGGCGATGTT
CCCAGGGCCAAGTTCACGAACATTTTCTTTAGTGAGATCATTGCCCCTCTCGTCCAAGTT
GCTGTGACTTTGGTTCCTTACCTCTACATCAACTCGAGAACTGGTATCTCCAATGACAAC
GAGCGGGCGTCAAATGCCGTGGTTCGTATTGCCATCGTCGCCTTCGGTCCCATCGGTGTT
AACGCCGGTGTCTCGGGTATGTTCTTCGGTATGGCTTGCTGTATGGGTCCCATCTTTGGC
ATGTGCTGCAAGAAGTTTGGTGCAGTCCTCGCTGCTATCGCTCACGCCATCGCGGTTATT
ATCCTGCTTGTCATTTTCGAGGTCATGTTCTTCCTTGAGAGCTGGTCCTGGCCTCGCATG
GTCCTGGGAATGATTTCTGCCGCTGCAATTCAGCGCTTCATCTACAAGCTGATCATCTCC
CTCGCCCTGACCAGAGAATTCAAGCATGACCAGTCGAACATCGCTTGGTGGACCGGAAAA
TGGTACAACATGGGTTGGCACTCGCTTTCCCAGCCTGGCAGAGAATTCCTGTGCAAGATT
ACCGAGCTTGGATACTTCTCTGCCGACTTTGTCCTGGGCCATATTCTCCTCTTTGTCATG
CTTCCTGCTCTCTGCATCCCCTATGTTGACAAGTTCCACTCCGTTATCCTCTTCTGGCTG
AGGCCTAGTCGTCAAATTCGCCCTCCCATCTACTCTCTGAAGCAGTCTAAGCTCCGCAAG
AGAAGAGTTGTCCGATTTGCGATTCTGTATTTCACTATGCTGGTTCTGTTCCTCATCCTT
CTCATTGCTCCTCTGGTTGCCCGGGATGAAGGCATCAGCGTGAACCTCAACATCATGAGC
CTTATGCAGCCTCTGGATACCGACAATAACGATACCATCTCCAGTTACACTGGTAATGGT
CTCCCTGTCGGTTACTCTGCCTGGACCCCGTCCGCGGCGTCTGCATCTGCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF14288</identifier>
            <name>FKS1_dom1</name>
          </pfam>
          <pfam>
            <identifier>PF02364</identifier>
            <name>Glucan_synthase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>1,3-beta-D-glucan synthase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1,3-beta-D-glucan synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>(1-&gt;3)-beta-D-glucan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002089</id>
      <name>Catechol O-methyltransferase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1936</ref-id>
            <pubmed-id>15882123</pubmed-id>
            <citation>Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509.</citation>
          </article>
          <article>
            <ref-id>A1939</ref-id>
            <pubmed-id>17516879</pubmed-id>
            <citation>Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.</citation>
          </article>
          <article>
            <ref-id>A33321</ref-id>
            <pubmed-id>22129592</pubmed-id>
            <citation>Julius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA: Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. J Antimicrob Chemother. 2012 Feb;67(2):422-9. doi: 10.1093/jac/dkr494. Epub 2011 Nov 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21964" source="Swiss-Prot">
        <name>Catechol O-methyltransferase</name>
        <general-function>O-methyltransferase activity</general-function>
        <specific-function>Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.</specific-function>
        <gene-name>COMT</gene-name>
        <locus>22q11.21-q11.23|22q11.21</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions>7-26</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.15</theoretical-pi>
        <molecular-weight>30036.77</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2228</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>COMT</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M65212</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>180920</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2472</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21964</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>COMT_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.1.1.6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004096|Catechol O-methyltransferase
MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRIL
NHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCG
YSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKY
DVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFE
CTHYQSFLEYREVVDGLEKAIYKGPGSEAGP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011516|Catechol O-methyltransferase (COMT)
ATGCCGGAGGCCCCGCCTCTGCTGTTGGCAGCTGTGTTGCTGGGCCTGGTGCTGCTGGTG
GTGCTGCTGCTGCTTCTGAGGCACTGGGGCTGGGGCCTGTGCCTTATCGGCTGGAACGAG
TTCATCCTGCAGCCCATCCACAACCTGCTCATGGGTGACACCAAGGAGCAGCGCATCCTG
AACCACGTGCTGCAGCATGCGGAGCCCGGGAACGCACAGAGCGTGCTGGAGGCCATTGAC
ACCTACTGCGAGCAGAAGGAGTGGGCCATGAACGTGGGCGACAAGAAAGGCAAGATCGTG
GACGCCGTGATTCAGGAGCACCAGCCCTCCGTGCTGCTGGAGCTGGGGGCCTACTGTGGC
TACTCAGCTGTGCGCATGGCCCGCCTGCTGTCACCAGGGGCGAGGCTCATCACCATCGAG
ATCAACCCCGACTGTGCCGCCATCACCCAGCGGATGGTGGATTTCGCTGGCGTGAAGGAC
AAGGTCACCCTTGTGGTTGGAGCGTCCCAGGACATCATCCCCCAGCTGAAGAAGAAGTAT
GATGTGGACACACTGGACATGGTCTTCCTCGACCACTGGAAGGACCGGTACCTGCCGGAC
ACGCTTCTCTTGGAGGAATGTGGCCTGCTGCGGAAGGGGACAGTGCTACTGGCTGACAAC
GTGATCTGCCCAGGTGCGCCAGACTTCCTAGCACACGTGCGCGGGAGCAGCTGCTTTGAG
TGCACACACTACCAATCGTTCCTGGAATACAGGGAGGTGGTGGACGGCCTGGAGAAGGCC
ATCTACAAGGGCCCAGGCAGCGAAGCAGGGCCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01596</identifier>
            <name>Methyltransf_3</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catechol O-methyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>magnesium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>O-methyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to phosphate starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>developmental process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrogen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal reproductive process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of homocysteine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>short-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme>
      <id>BE0003195</id>
      <name>Arylsulfatase A</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1936</ref-id>
            <pubmed-id>15882123</pubmed-id>
            <citation>Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509.</citation>
          </article>
          <article>
            <ref-id>A1939</ref-id>
            <pubmed-id>17516879</pubmed-id>
            <citation>Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P15289" source="Swiss-Prot">
        <name>Arylsulfatase A</name>
        <general-function>Sulfuric ester hydrolase activity</general-function>
        <specific-function>Hydrolyzes cerebroside sulfate.</specific-function>
        <gene-name>ARSA</gene-name>
        <locus>22q13.31-qter|22q13.33</locus>
        <cellular-location>Lysosome</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.01</theoretical-pi>
        <molecular-weight>53587.6</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:713</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ARSA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X52151</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P15289</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ARSA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.6.8</synonym>
          <synonym>ASA</synonym>
          <synonym>Cerebroside-sulfatase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006234|Arylsulfatase A
MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTPNLDQLAAGGLRFT
DFYVPVSLCTPSRAALLTGRLPVRMGMYPGVLVPSSRGGLPLEEVTVAEVLAARGYLTGM
AGKWHLGVGPEGAFLPPHQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIP
LLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTHYPQFSGQSFAE
RSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETMRMSRGGCSGLLRC
GKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGAPLPNVTLDGFDLSP
LLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSL
TAHEPPLLYDLSKDPGENYNLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARG
EDPALQICCHPGCTPRPACCHCPDPHA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021348|Arylsulfatase A (ARSA)
ATGTCCATGGGGGCACCGCGGTCCCTCCTCCTGGCCCTGGCTGCTGGCCTGGCCGTTGCC
CGTCCGCCCAACATCGTGCTGATCTTTGCCGACGACCTCGGCTATGGGGACCTGGGCTGC
TATGGGCACCCCAGCTCTACCACTCCCAACCTGGACCAGCTGGCGGCGGGAGGGCTGCGG
TTCACAGACTTCTACGTGCCTGTGTCTCTGTGCACACCCTCTAGGGCCGCCCTCCTGACC
GGCCGGCTCCCGGTTCGGATGGGCATGTACCCTGGCGTCCTGGTGCCCAGCTCCCGGGGG
GGCCTGCCCCTGGAGGAGGTGACCGTGGCCGAAGTCCTGGCTGCCCGAGGCTACCTCACA
GGAATGGCCGGCAAGTGGCACCTTGGGGTGGGGCCTGAGGGGGCCTTCCTGCCCCCCCAT
CAGGGCTTCCATCGATTTCTAGGCATCCCGTACTCCCACGACCAGGGCCCCTGCCAGAAC
CTGACCTGCTTCCCGCCGGCCACTCCTTGCGACGGTGGCTGTGACCAGGGCCTGGTCCCC
ATCCCACTGTTGGCCAACCTGTCCGTGGAGGCGCAGCCCCCCTGGCTGCCCGGACTAGAG
GCCCGCTACATGGCTTTCGCCCATGACCTCATGGCCGACGCCCAGCGCCAGGATCGCCCC
TTCTTCCTGTACTATGCCTCTCACCACACCCACTACCCTCAGTTCAGTGGGCAGAGCTTT
GCAGAGCGTTCAGGCCGCGGGCCATTTGGGGACTCCCTGATGGAGCTGGATGCAGCTGTG
GGGACCCTGATGACAGCCATAGGGGACCTGGGGCTGCTTGAAGAGACGCTGGTCATCTTC
ACTGCAGACAATGGACCTGAGACCATGCGTATGTCCCGAGGCGGCTGCTCCGGTCTCTTG
CGGTGTGGAAAGGGAACGACCTACGAGGGCGGTGTCCGAGAGCCTGCCTTGGCCTTCTGG
CCAGGTCATATCGCTCCCGGCGTGACCCACGAGCTGGCCAGCTCCCTGGACCTGCTGCCT
ACCCTGGCAGCCCTGGCTGGGGCCCCACTGCCCAATGTCACCTTGGATGGCTTTGACCTC
AGCCCCCTGCTGCTGGGCACAGGCAAGAGCCCTCGGCAGTCTCTCTTCTTCTACCCGTCC
TACCCAGACGAGGTCCGTGGGGTTTTTGCTGTGCGGACTGGAAAGTACAAGGCTCACTTC
TTCACCCAGGGCTCTGCCCACAGTGATACCACTGCAGACCCTGCCTGCCACGCCTCCAGC
TCTCTGACTGCTCATGAGCCCCCGCTGCTCTATGACCTGTCCAAGGACCCTGGTGAGAAC
TACAACCTGCTGGGGGGTGTGGCCGGGGCCACCCCAGAGGTGCTGCAAGCCCTGAAACAG
CTTCAGCTGCTCAAGGCCCAGTTAGACGCAGCTGTGACCTTCGGCCCCAGCCAGGTGGCC
CGGGGCGAGGACCCCGCCCTGCAGATCTGCTGTCATCCTGGCTGCACCCCCCGCCCAGCT
TGCTGCCATTGCCCAGATCCCCATGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00884</identifier>
            <name>Sulfatase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arylsulfatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cerebroside-sulfatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sulfuric ester hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycosphingolipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-translational protein modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sphingolipid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>